Fine Foods & Pharmaceuticals Ntm Logo

Fine Foods & Pharmaceuticals Ntm

Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.

FF | XMIL

Overview

Corporate Details

ISIN(s):
IT0005215329 (+1 more)
LEI:
8156009111DEE8553765
Country:
Italy
Address:
VIA BERLINO, 39 (ZINGONIA), 24040 VERDELLINO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fine Foods & Pharmaceuticals Ntm is an integrated Contract Sales and Development Manufacturing Organization (CSDMO) that serves as a strategic manufacturing partner for third parties. The company specializes in the development and production of oral solid forms for the pharmaceutical and nutraceutical sectors, as well as products for the cosmetics, medical device, and biocide industries. It leverages over 100 manufacturing lines and a strong focus on scientific innovation, with a significant portion of its workforce dedicated to science and R&D. Fine Foods emphasizes technological excellence, quality, reliability, and a long-standing commitment to ESG principles to support its clients' growth objectives.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 11:51
Director's Dealing
Allegato 3F / Annex 3F
Italian 28.8 KB
2025-09-29 12:11
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 22 SETTEMBRE – 26 SETTEMBRE 2…
Italian 452.8 KB
2025-09-22 11:05
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 15 SETTEMBRE – 19 SETTEMBRE 2…
Italian 468.2 KB
2025-09-15 12:06
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 8 SETTEMBRE – 12 SETTEMBRE 202…
Italian 458.0 KB
2025-09-10 18:21
Interim Report
Half-year Financial Report as of 30 June 2025
English 2.8 MB
2025-09-08 11:24
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 1 SETTEMBRE – 5 SETTEMBRE 2025…
Italian 476.9 KB
2025-09-02 14:17
Director's Dealing
Allegato 3F / ANNEX 3F
Italian 28.6 KB
2025-08-25 13:01
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 18 AGOSTO – 22 AGOSTO 2025 / …
English 500.7 KB
2025-08-18 12:40
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 11 AGOSTO – 14 AGOSTO 2025 / …
Italian 482.1 KB
2025-08-08 12:38
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 4 AGOSTO – 7 AGOSTO 2025 / TR…
Italian 450.2 KB
2025-08-06 11:22
Report Publication Announcement
Publication Notice – Half-year Financial Report as of 30 June 2025
English 263.9 KB
2025-08-06 11:21
Report Publication Announcement
Avviso di pubblicazione della Relazione Finanziaria semestrale al 30 giugno 2025
Italian 275.2 KB
2025-08-06 11:16
Interim Report
Relazione finanziaria semestrale al 30 giugno 2025
Italian 3.5 MB
2025-08-05 14:29
Earnings Release
Growing revenue Adjusted EBITDA was €21.6 million, +35%, and margins for 16.8%
English 579.2 KB
2025-08-05 14:28
Earnings Release
Ricavi in crescita EBITDA Adj. a €21,6 milioni, +35%, e marginalità al 16,8%
Italian 535.2 KB

Automate Your Workflow. Get a real-time feed of all Fine Foods & Pharmaceuticals Ntm filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Fine Foods & Pharmaceuticals Ntm via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.